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ABSTRACT
Objectives: The objective of the present study is taste masking of bitter clarithromycin using Indion 204, Indion 234, and Tulsion 335 as ion-exchange 
resins, which forms insoluble complexes, inhibiting the drug release in saliva as ion-exchange resins are cross-linked polymers, water-insoluble that 
contains salt-forming groups in repeating positions on the polymer chain. Drugs that are bitter and cationic get adsorbed onto weak cationic exchange 
resins of carboxylic acid functionality such as Indion 204, Indion 234, and Tulsion 335 to form non-bitter complexes.
Methods: The drug-resin complex loading process was optimized for the resin content, activation, swelling time, stirring time, influence of pH, 
and temperature for maximum drug loading and the formed complex was evaluated by differential scanning calorimetry (DSC) to confirm complex 
formation. The drug-resin complex was also characterized by their micromeritic and rheological properties. These complexes were used to prepare 
oral reconstituted suspensions and the taste was evaluated. The formulation was evaluated for various parameters such as sedimentation volume, pH, 
redispersibility, viscosity, drug content, and in vitro drug release.
Results: Acid-activated resins comprising Indion 204, Indion 234, and Tulsion 335 with the drug:resin ratio of 1:2, stirred in a solution of pH 7–8 
at 70° for 6 h had a maximum drug loading and masked the bitter taste of clarithromycin. DSC of the drug-resin complex (DRC) revealed that there 
was interaction leading to complex formation. The drug-resin complex was formulated into suspension formulations (S1-S9) and evaluated. Various 
parameters were found to be within permissible limits. Formulations S3, S6, and S9 containing 1:2 ratios of the drug-resin complex of Indion 204, 
Indion 234, and Tulsion 335 revealed maximum taste masking. This was further confirmed by treatment of taste evaluation scores obtained from 
the volunteers by ANOVA, Dunnett’s multiple comparison test, and Tukey’s multiple comparison test. All the three optimized formulations had a 
significant difference of p<0.001 when compared to control S10. S6 formulation was widely accepted.
Conclusion: Ion-exchange complexation could efficiently mask the bitter taste of clarithromycin and achieve palatable taste suitable for pediatric use.
Keywords: Ion-exchange resins, Drug-resin complex, Taste masking, Indion 204, 234, Tulsion 335, Dunnett’s test, Tukey’s test, ANOVA.
INTRODUCTION
The ease of administration is the criterion for the preference of oral 
dosage forms. The bitterness of active pharmaceutical ingredients (API) 
is one of the significant issues of the pharmaceutical industry during the 
formulation of dosage form, thereby leading to poor patient compliance. 
A majority of drugs are bitter due to the presence of amine functional 
groups, thereby rendering unpleasant taste to the formulation [1]. 
Hence, it becomes a challenge to the formulator to ensure that the 
bitterness and obnoxious taste of drugs is masked particularly in 
pediatric and geriatric formulations dosage form thereby ensuring that 
the formulation is patient compliant and has product value [2].
Ion-exchange resins are economical and can be incorporated in the 
development of a basic, rapid, and profitable method of taste masking [3]. 
Ion-exchange resins are polymeric cross-linkage chains containing salt 
forming groups in repeating position, which have an affinity for oppositely 
charged counter ions, thus adsorbing and binding the ions into the 
polymer matrix in an equilibrium process. The bound drug is desorbed 
or eluted from the drug-resin complex during the process of absorption 
into the body [4,5]. The versatility of IER as drug delivery vehicles has 
attracted pharmaceutical research [6]. Ion-exchange resins are used 
for masking of taste, sustained release, targeted drug delivery, and drug 
stabilization [7]. Weak cationic exchange resin of carboxylic acid is used 
for masking bitter cationic drugs to form a non-bitter complex [8].
Clarithromycin is a macrolide antibiotic used in the treatment 
of common pediatric infections of the middle ear and upper 
respiratory tract as well as certain forms of pneumonia that affect the 
elderly [9]. However, the drug is very bitter making oral administration 
of the drug [10]. It is a practically water-insoluble drug and shows 
polymorphism and the problem of stability by hydrolysis when 
it is in a liquid formulation for a long time [10]. Commercially, it is 
available as a tablet and suspensions but these formulations possess 
a problem of drug release in the saliva. Hence, it is an objective of 
the present research to provide an oral reconstituted suspension of 
clarithromycin which can deliver pharmaceutically acceptable and 




Clarithromycin was obtained as a gift sample from Ind-Swift 
Laboratories Limited, Punjab. Indion 204 and Indion 234 were gifted by 
Ion Exchange India Ltd., Mumbai. Tulsion-335 was gifted by Thermax 
Ltd., Pune. Xanthan gum was obtained from HiMedia, Mumbai. Sodium 
Benzoate, sucrose, sodium citrate, and flavor were purchased from S.D 
Fine-Chem. Ltd., Mumbai. Aspartame was purchased from NutraSweet 
Company and all the chemicals were used of either pharma or analytical 
grade.
© 2020 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2020.v13i3.36438
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Taste evaluation of formulation was performed by volunteers within 
the age group of 21–25 years. Prior explanation of the study protocol 
and written consent was obtained from the volunteers [11].
Methods
Standard calibration curve of clarithromycin
The samples of different concentrations of range 20–120 µg/mL were 
prepared with chloroform. To 10 mL of each dilution taken in separating 
funnel, 5 mL concentrated hydrochloric acid was added followed by 
10 mL of acetone and reaction mixture was shaken gently for 5 min 
for the formation of a stable orange-colored complex [12]. The upper 
orange-red colored layer was separated and the absorbance measured 
at 486 nm against reagent blank [12].
Complexation with ion-exchange resin
Optimization of drug-resin complexation
The loading of the drug onto the resin was optimized for various 
parameters during processing, including activation conditions, swelling 
time, stirring time, pH, temperature, and drug:resin ratio [13].
Effect of activation conditions on resin drug loading capacity
Activation of Indion 204, Indion 234, and Tulsion 335 was done by 
washing the individual resins with deionized water, 1N HCl and 1N 
NaOH in separate processes. The resin was further subjected to repeated 
washing with water until neutral pH was reached. Drug-resin complexes 
(DRC) were prepared by adding 100 mg of activated resin that was 
swollen for 45 min into a beaker containing 50 mL of distilled water and 
100 mg of the drug. The mixture was prepared as a slurry with the aid of 
magnetic stirrer for 6 h at 60°C. The residue of the mixture was washed 
with 100 mL of chloroform and filtered. From this solution, 0.5 mL was 
taken and diluted to 10 mL with chloroform. The unbound amount drug in 
the filtrate was estimated spectrophotometrically at λmax 486 nm [12,13].
Optimization of resin concentration for maximum drug loading
Acid activated swollen resins and drugs were added in the ratio of 1:1, 
1:1.5, and 1:2–100 mL of deionized water in separate beakers and 
stirred using a magnetic stirrer for 6 h at 60°C. The mixture residues 
were filtered and were washed with chloroform. The drug-loading 
efficiency of the resin was estimated [12,13].
The optimized resin concentration for the maximum loading of the drug 
was estimated spectrophotometrically (Table 1).
Optimization of swelling time of resin for maximum drug loading
Various batches of acid-activated resins were soaked in 100 mL 
quantity of deionized water for 10, 20, 30, 40, 50, 60, and 70 min at 
60°C temperature in separate beakers. To each beaker drug and resin 
were added at 1:2 ratio and mixtures were stirred for 6 h at 60°C. Resin 
drug-loading efficiency was estimated [12,13]. The optimized swelling 
time of resin required for maximum drug loading was estimated 
spectrophotometrically (Table 2).
Optimization of stirring time for maximum drug loading
1:2 ratio of drug-resin complexes of separate batches was slurred 
in 100 mL of deionized water for 30, 60, 120, 180, 240, 300, and 
360 min with the aid of magnetic stirrer at 60°C. Resin drug-loading 
efficiency was estimated [12,13]. The optimized stirring time required 
for maximum drug loading was estimated spectrophotometrically 
(Table 2).
Optimization of processing temperature for maximum drug loading
1:2 ratio of drug-resin complexes of separate batches was slurred in 
100 mL of deionized water at different temperatures, namely, 25°, 30°, 
40°, 50°, 60°, and 70°C using temperature controlled magnetic stirrer 
for 6 h. The amount of resin drug-loading efficiency was estimated 
spectrophotometrically from the bound drug. The optimized processing 
temperature was obtained [12,13] (Table 3).
Optimization of pH for maximum drug loading
1:2 ratio of drug-resin complexes of separate batches were slurred 
in 100 mL of standard solutions of hydrochloric acid and sodium 
hydroxide having pH 1.2, 2, 5, 6, 7, and 8 and stirred using a magnetic 
stirrer for 6 h at 60°C. The drug-loading efficiency was estimated and 
pH was optimized for maximum drug loading [12,13] (Table 3).
Preparation of drug-resin complexes
Based on optimization study results, batches of drug-resin complexes 
at 1:1, 1:1.5, and 1:2 ratio were prepared at optimized conditions for 
maximum loading capacity and subjected to further evaluation [13].
Evaluation of the optimized drug-resin complexes for drug content
The drug content was determined by eluting the 250 mg of DRC with 
continuous stirring in 100 mL 1N HCl for 1 h to ensure complete 
elution [13]. The solution was filtered. After suitable dilution, the drug 
content was determined spectrophotometrically at λmax 486 nm and the 
readings were taken in triplicate.
Table 1: Effect of activation conditions and resin concentration for maximum drug loading
Resins Percentage of drug bound to resin in various 
activation conditions (%)
Percentage of drug bound to various resins (%)
Inactivated Acid Base 1:1 1:1.5 1:2
Indion 204 45.26±0.68 66.92±0.83 52.16±0.34 67.15±0.28 75.01±0.40 86.67±0.26
Indion 234 44.59±0.77 66.30±0.72 50.54±0.64 67.87±0.56 75.01±0.29 86.81±0.36
Tulsion 335 44.30±0.48 67.06±0.39 50.73±0.65 70.01±0.63 77.39±0.58 87.14±0.45
Results are mean±standard deviation (n=3)
Table 2: Optimization of swelling time and stirring time for maximum drug loading
Swelling time (min) Percentage of drug bound to various 
resins (%)
Stirring time (min) Percentage of drug bound to various 
resins (%)
Indion 204 Indion 234 Tulsion 335 Indion 204 Indion 234 Tulsion 335
10 70.72±0.32 65.49±0.17 66.20±0.69 30 60.73±0.62 58.58±0.89 60.25±0.88
20 79.29±0.94 75.86±0.75 70.96±0.64 60 65.96±0.36 65.49±0.98 66.20±0.35
30 80.19±0.17 79.81±0.98 78.43±0.76 120 71.20±0.55 70.82±0.79 70.96±0.48
40 83.67±0.70 83.05±0.37 83.14±0.47 180 76.91±0.88 74.86±0.97 75.01±0.68
50 85.91±0.67 85.29±0.87 86.62±0.39 240 80.72±0.69 79.62±0.78 79.29±0.46
60 86.91±0.46 85.29±0.62 87.86±0.63 300 84.76±0.46 83.43±0.69 82.62±0.73
70 86.91±0.59 85.29±0.69 88.1±0.78 360 86.67±0.78 85.81±0.87 86.19±0.61
Results are mean±standard deviation (n=3)
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Evaluation of the prepared drug-resin complexes for drug release
The drug release studies were performed by the USP Type XXIII tablet 
dissolution apparatus. DRC equivalent to 250 mg of clarithromycin was 
taken in 900 mL of 0.1 N HCl. The temperature and speed of the apparatus 
were maintained at 37±0.5°C and 75 rpm, respectively. Aliquots 
were withdrawn after every 2 min for 30 min and were filtered with 
Whatman filter paper no. 41 and were analyzed spectrophotometrically 
at λmax 486 nm. Triplicate readings were taken [13,14].
Differential scanning calorimetry (DSC) was carried out for the 
characterization of the complex formed. All the DRCs were subjected 
to DSC and the thermograms were studied for drug-polymer complex 
formation [13-15].
Micromeritics: The DRCs were evaluated for the angle of repose, Carr’s 
index, tapped and bulk density, and Hausner’s ratio [13].
Formulation of the prepared drug-resin complexes into dry 
powder suspension
Accurately weighed amounts of the prepared complexes of clarithromycin 
resinates (Indion 204, Indion 234, and Tulsion 335) at 1:1, 1:1.5, and 1:2 
drug:resin ratios equivalent to 250 mg of clarithromycin were mixed 
with other excipients such as suspending agents, sweetener, flavoring 
agent, preservative, anti-caking agent, and buffer by conventional 
technique [16,17]. All the ingredients were passed through 44# and 
mixed. The dry suspension is reconstituted up to 100 ml with distilled 
water before use. The formulations S1-S9 represented with DRC and 
S10 represented without DRC (Table 4).
Evaluation parameters
The angle of repose, Carr’s index, as well as the Hausner’s ratio for 
drug powder and dry powder suspension, were determined and 
compared [13].
Evaluation of the prepared oral reconstituted suspensions
100 mL of a reconstituted oral suspension of clarithromycin was 
prepared and fully evaluated for color and odor, viscosity, pH, 
sedimentation rate, redispersibility, and particle size [16-18].
Furthermore, drug content, drug leaching into the suspension, and 
in vitro dissolution studies of the drug from the prepared suspensions 
were determined and compared [17-19].
Assessment of the bitter taste of drug (bitterness threshold)
The bitter taste threshold value of clarithromycin was determined based 
on the bitter taste recognized by six volunteers. Before measurement, 
informed written consent was taken from each volunteer [20].
Various concentrations (10–100 μg/mL) of the drug were prepared in 
phosphate buffer pH 6.7. The buffer solution was used for rinsing the 
mouth and then, l0 mL of the most dilute solution was swirled in the 
mouth near the base of the tongue for 30 s and tasted. After 30 s, if 
the bitter sensation was no longer felt in the mouth, the solution was 
spat out and wait for 1 min to ascertain whether this is due to delayed 
sensitivity. Then rinse with safe drinking water. The recording was.
“−” = Did not detect any difference in taste
“+” = Detected some difference but was not able to specify about the 
taste and
“++” = Detected a bitter taste.
The next highest concentration should not be tasted until at least 10 min 
have passed. The threshold of the bitterness of the drug is defined as 
the concentration at which more than half of the volunteers detected 
bitterness when holding the drug in their mouth. The threshold value 
was correspondingly selected from the different drug concentrations as 
the lowest concentration that had a bitter taste [21] (Table 5).
In vivo evaluation of the bitter taste of the formulations
Gustatory sensation tests of prepared suspensions were done using the 
equivalent density examination method [21]. The pure drug formulation 
was kept as control during the study. Before the experiment, the 
study protocol was explained and written consent was obtained from 
volunteers (n=6; three males and three females). Prepared formulae 
were kept in the mouth by each volunteer and the bitterness level was 
recorded against a standard using a numerical scale. The standard 
quinine hydrochloride concentrations used were 0.01, 0.03, 0.10, 0.30, 
Table 3: Optimization of processing temperature and pH for maximum drug loading
Temperature (°C) Percentage of drug bound to various resins (%) pH Percentage of drug bound to various resins (%)
Indion 204 Indion 234 Tulsion 335 Indion 204 Indion 234 Tulsion 335
25 74.25±0.69 72.82±0.58 74.25±0.53 1.2 49.26±0.86 48.07±0.38 54.74±0.57
30 76.87±0.47 74.9±0.46 74.97±0.58 2 54.50±0.35 51.17±0.55 59.26±0.78
40 79.73±0.53 78.06±0.73 80.44±0.33 5 68.30±0.35 68.30±0.59 75.92±0.77
50 82.34±0.98 82.87±0.59 83.06±0.98 6 76.63±0.65 75.20±0. 87 79.25±0.46
60 86.39±0.53 85.77±0.28 86.39±0.46 7 86.15±0.69 84.01±0.59 85.44±0.68
70 89.48±0.27 87.72±0.85 88.77±0.92 8 88.53±0.58 86.39±0.66 87.58±0.35
Results are mean±standard deviation (n=3)
Table 4: Formulation table for oral reconstituted suspension
S. No. Ingredients Gram per tablet
S1 S2 S3 S4 S5 S6 S7 S8 S9 S10
1. Drug* - - - - - - - - - 250 mg
2. DRC Indion 204 6.41 g 7.62 8.15 - - - - - - -
3. DRC Indion 234 - - - 6.94 7.91 8.42 - - - -
4. DRC Tulsion 335 - - - - - - 6.66 7.81 8.42 -
5. Xanthan gum 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3
6. Sodium benzoate 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
7. Aspartame 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25
8. Aerosil 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
9. Sodium citrate 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3
10. Sucrose 2.13 1.42 0.60 1.60 0.63 0.12 1.89 0.74 0.12 6.05
11. Total weight* 11 11 11 11 11 11 11 11 11 11
12. Lake sunset yellow q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s
13. Flavor 1 ml 1 m 1 ml 1 ml 1 ml 1 ml 1 ml 1 ml 1 ml 1 ml
Dose of clarithromycin* - 125 mg/5 mL. DRC: Drug-resin complex. *Reconstituted with 100 mL of water at the time of use
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and 1.00 mM and the corresponding bitterness scores were defined as 
0, 1, 2, 3, and 4, respectively. Before testing, the volunteers are given the 
standard quinine solutions and asked to swirl in their mouths and were 
told the concentrations and bitterness scores of each solution [22]. 
After tasting a test formulation suspended in water, they were asked 
to give the sample a bitterness score in comparison to the standard. 
All samples were kept in the mouth for 15 s. After testing the sample, 
the volunteers rinsed their mouths well and waited for at least 20 min 
before tasting the next sample. The average scores for bitterness, 
flavor, mouthfeel, and overall acceptability for each formulation were 
calculated and also the standard deviation was arrived (Table 6).
Statistical analysis
The scores were then interpreted by one-way ANOVA [23] using 
GraphPad Prism Version 5.0 Software. Dunnett’s multiple comparison 
test was used for comparing all the formulations (S1-S9) with the 
control formulation (S10). The statistical significance was then 
interpreted. Tukey’s multiple comparison tests are used for comparing 
the scores within the groups with different ratios of the same resins, 
and then the formulations having the highest significance levels from 
each group were compared [24].
RESULTS AND DISCUSSION
Optimization of drug-resin complexation and resin concentration 
for maximum drug loading is presented in Table 1. Optimization of 
swelling time and stirring time of resin for maximum drug loading is 
shown in Table 2. Optimization of processing temperature and pH for 
maximum drug loading is presented in Table 3. The loading capacity of 
the resin for clarithromycin was higher in the acid-activated condition 
when compared to alkaline conditions. This could be explained by the 
stoichiometric exchange nature reaction between drug and resin in 
solution. All resins displayed an increase in drug loading capacity with 
an increase in swelling time. It was found that as the time of stirring of 
the solution increased, the drug loading also increased and maximum 
drug loading was achieved within 6 h.
The effect of temperature for optimization is necessary, as, at higher 
temperatures, the ion diffusion increased. The percent drug-loaded 
increased with the rise in pH, which was due to the nature of the 
used resins and drug where the ionization was favored at pH 8. DRC 
comprising Indion 204, Indion 234, and Tulsion 335 at maximum 
drug-resin ratio (1:2) exhibited drug content in a range of 92.10±0.59%, 
89.01±0.55%, and 89.01±0.46%, respectively, and faster dissolution 
when compared to the pure drug (Fig. 1).
DSC thermograms of drug, resin, and DRC are depicted in Fig. 2.
DRC displayed good micromeritic properties with the angle of 
repose ranging from 26° 12±0.57 to 29° 38±0.47, bulk density values 
of 0.419±0.01–0.472±0.01 g/cm3, tapped density of 0.505±0.07–
0.575±0.07 g/cm3, percent compressibility index of 13.461±0.89–
17.913±0.73, and Hausner’s ratio of 1.155±0.08–1.218±0.07. Dry powder 
suspension parameters were evaluated. The powder displayed angle of 
repose from 22° 59±0.88 to 25° 69±0.73, bulk density of 0.442±0.01–
0.479±0.04 g/cm3, tapped density of 0.52±0.06–0.541±0.07 g/cm3, 
percent compressibility index values from 10.800±0.69 to 15.163±0.55, 
and Hausner’s ratio ranging from 1.121±0.06 to 1.78±0.07. The dry 
powder displayed good micromeritic properties with the angle of 
repose ranging from 22° 59±0.88 to 25°69±0.73, bulk density values 
of 0.442±0.01–0.479±0.04 g/cm3, tapped density of 0.520±0.06–
0.543±0.08 g/cm3, percent compressibility index of 10.800±0.69–
15.163±0.55, and Hausner’s ratio of 1.121±0.06–1.160±0.08.
Table 6: Preference points for standard bitterness and 
palatability
Score Mouthfeel Flavor Overall acceptability
0 No No No
1 Gritty Poor Poor
2 Smooth Acceptable Acceptable
3 Creamy Good Good
4 Very creamy Very good Very good
Table 5: Determination of bitterness threshold of 
clarithromycin
Concentration (µg/ml) Volunteers
1 2 3 4 5 6
10 − − − − − −
20 − − − − − −
30 − − − − − −
40 − − − − − −
50 − − − − + +
60 + + − − + +
70 + + − + + +
80 + + + + + +
90 + ++ + + ++ +
100 ++ ++ ++ ++ ++ ++
−Non bitter, +bitter, ++threshold bitterness
Fig. 1: In vitro dissolution release profiles of resin complex 
exhibiting maximum drug release. Errors bars represent 
the standard deviation of n=3, DRC3 (drug-resin complex 
3–Indion 204) (▬●▬); DRC6 (drug-resin complex 6–Indion 234) 
(▬■▬); DRC9 (drug-resin complex 9–Tulsion 255) (▬▲▬)
Fig. 2: The DSC thermograms of clarithromycin and thermograms 
of the drug-resinate mixtures. Drug-clarithromycin; R1–Indion; 
R2–Indion; R3–Tulsion; DRC3–Drug:resin Indion 204 (1:2); DRC6–
Drug:resin Indion 234 (1:2); DRC9–Drug:resin Tulsion 255 (1:2)
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All the prepared oral reconstituted suspensions (S1-S10) were 
subjected to evaluation. The ranges of viscosity was found to be 
225.6±0.76–273.2±0.44 cps, pH was found to be 7.1±0.04–7.4±0.06, 
sedimentation rate was found to be 0.95–0.99 on 0th day and 0.93–0.98 
on 7th day, redispersibility was found to be + on 0th day and + on 7th day, 
and drug content was found to be 97.57±0.69–98.99±0.66%, and 
particle size was found to be 97.89±0.57–168.97±0.97 µm.
All the formulations comprising DRC displayed rapid drug release when 
compared to S10 formulations. S3, S6, and S9 formulations exhibited 
a release 98.64±0.356%, 99.05±0.239%, and 98.85±0.303% in 14 min, 
respectively, other formulations exhibited release within 16–24 min. 
S10 formulations displayed a release of 98.02±0.432% after 24 min 
(Fig. 3). Thus, from the release studies, it was evident that the ion-
exchange resins can also act as dissolution enhancers apart from taste 
masking.
The threshold for the bitterness of clarithromycin was detected by 
varying its concentration, and threshold value was obtained from 
volunteers (n=6) (Table 5). The reference points for standard bitterness 
and palatability are shown in Table 6.
Dunnett’s test was performed to evaluate bitterness and overall 
acceptability of S1-S9 in comparison to S10 formulation without DRC 
(Table 7). Tukey’s test was performed to evaluate bitterness and overall 
acceptability by selecting one formulation which was significantly 
different from each of the three groups, i.e., S3 (from group of S1, S2, 
and S3), S6 (from group of S4, S5, and S6), and S9 (from group of S7, 
S8, and S9), as shown in Table 8. The drug loading capacity of the resin 
was increased in acidic activated conditions than in alkaline activated 
conditions and this is due to the cationic nature of the used resin 
(Indion 204) since the COO- group of the Indion is loaded by H+ of the 
acid but not OH- of the base. As the polymer concentration increased, 
the amount of drug-loaded onto all the resins also increased due to the 
stoichiometric exchange nature of the reaction in solution between 
drug and resin.
All the resins displayed an increase in drug loading capacity with 
an increase in swelling time; therefore, the time of swelling has to 
be established. The rate and extent of the ion-exchange process are 
increased if the resin is swollen and hydrated. In the unswollen resin 
matrix, the exchangeable groups are latent and remain coiled toward 
their backbone. Swelling increases the surface area and these groups 
are oriented toward outside. It was found that maximum drug loading 
was achieved within 6 h with an increase in the time of stirring the 
solution.
Fig. 3: In vitro cumulative percentage drug released from 
suspensions versus time. Optimized formulations versus control. 
Errors bars represent the standard deviation of n=3, S3 (▬●▬); 
S6 (▬■▬); S9 (▬▲▬); S10 (▬ ▼ ▬ )
Table 7: Dunnett’s test for bitterness, mouthfeel, and overall 









S10 versus S1 3.83±0.4082 2.16±0.408 ***
S10 versus S2 1.5±0.547 ***
S10 versus S3 0.33±0.516 ***
S10 versus S4 2.33±0.516 ***
S10 versus S5 1.33±0.516 ***
S10 versus S6 0.16±0.408 ***
S10 versus S7 2.16±0.408 ***
S10 versus S8 1.33±0.516 ***








S10 versus S1 2.00±0.6325 2.00±0.632 ns
S10 versus S2 1.66±0.516 ns
S10 versus S3 2.00±0.894 ns
S10 versus S4 2.16±0.752 ns
S10 versus S5 1.83±0.752 ns
S10 versus S6 1.66±0.516 ns
S10 versus S7 1.83±0.752 ns
S10 versus S8 2.00±0.632 ns








S10 versus S1 3.00±0.000 0.408 ns
S10 versus S2 3.33±0.516 ns
S10 versus S3 3.50±0.547 *
S10 versus S4 3.66±0.516 **
S10 versus S5 4.00±0.000 *
S10 versus S6 3.83±0.408 ns
S10 versus S7 2.83±0.752 ns
S10 versus S8 3.00±0.000 ns
S10 versus S9 3.00±0.000 ns








S10 versus S1 0.16±0.4082 1.16±0.408 **
S10 versus S2 1.66±0.514 ***
S10 versus S3 3.50±0.547 ***
S10 versus S4 1.50±0.547 ***
S10 versus S5 2.16±0.400 ***
S10 versus S6 4.00±0.000 ***
S10 versus S7 1.16±0.408 **
S10 versus S8 1.33±0.516 ***
S10 versus S9 3.33±0.516 ***
S10 versus S1 1.16±0.408 **
***p<0.001, **p<0.01, *p<0.05, nsp=non-significant results are mean±standard 
deviation (n=3). SD: Standard deviation
The effect of temperature on the exchange reactions showed that as 
the temperature rises, the exhaustive exchange zone is markedly 
shrunk, through which there is an increase in the ion diffusion rate. 
The percentage drug-loaded increased with increased pH; this is due 
to the nature of the used resin and drugs where the ionization was 
favored at pH 8. The decreased complexation at higher pH is because 
at higher pH, the solution becomes basic and cationic ion of resin 
gets saturated with the basic solution, thereby hindering the drug 
attachment. The decreased complexation at lower pH is because of an 
acidic environment the resin existed as a free acid in a non-ionic state 
and all the drug is released in the filtrate. The evaluated parameters 
were within the acceptable range. The in vitro dissolution studies were 
carried out for all the 9 DRC formulations and found to be excellent. 
The percentage drug released from 1:2 ratios of all the DRC was higher. 
The percentage of drug released from 1:2 ratio DRC6 of Indion 234 
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accepted by the volunteers. In the case of Dunnett’s test and Tukey’s 
test for mouthfeel evaluation, S1-S9 when compared to S10 showed 
no significant difference. Hence, all the formulations have significantly 
same mouthfeel when compared to S10. This concludes that the 
addition of resins to the formulation did not alter the mouthfeel of 
the suspensions. From the above data, it can be concluded that ion-
exchange complexation of clarithromycin with Indion 204, Indion 234, 
and Tulsion 335 could efficiently mask the bitter taste and achieve 
palatable taste suitable for pediatric use.
CONCLUSION
Taste masking could be effectively achieved by the use of ion-exchange 
resins as it was found to be a safe, commercially inexpensive and easy 
method to achieve taste-masked complex of a bitter drug with a smooth 
feel. The taste-masked complex was successfully developed as an oral 
reconstituted suspension that can be considered as the geriatric and 
pediatric friendly dosage form.
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